Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04611789 | A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | PHASE1 | COMPLETED | 18 | — | — | Nov 2, 2020 | Feb 10, 2021 | Dec 6, 2021 | 1 | United States |
| NCT04441931 | A Study of LY3832479 (LY-CoV016) in Healthy Participants | PHASE1 | COMPLETED | 26 | — | — | Jun 19, 2020 | Oct 2, 2020 | Dec 6, 2021 | 1 | United States |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to tlast (AUC\[0-tlast\]) of LY3832479.
PK: Maximum Serum Concentration (Cmax) of LY3832479.
The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Arm | Type | Description |
|---|---|---|
| LY3832479 | EXPERIMENTAL | Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479. |
| Placebo | PLACEBO_COMPARATOR | Participants received single subcutaneous dose of Placebo. |
| Name | Type | Description |
|---|---|---|
| LY3832479 | DRUG | Administered subcutaneously |
| Placebo | DRUG | Administered subcutaneously |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history and physical examination * Are willing to follow study procedures, including having nasal or nasopharyngeal swabs collected * Have a body mass index (BMI) within the range of greater than or equa...